Albandar, H.J.; Fuqua, J.; Albandar, J.M.; Safi, S.; Merrill, S.A.; Ma, P.C.
Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not? Cancers 2021, 13, 989.
https://doi.org/10.3390/cancers13050989
AMA Style
Albandar HJ, Fuqua J, Albandar JM, Safi S, Merrill SA, Ma PC.
Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not? Cancers. 2021; 13(5):989.
https://doi.org/10.3390/cancers13050989
Chicago/Turabian Style
Albandar, Heidar J., Jacob Fuqua, Jasim M. Albandar, Salahuddin Safi, Samuel A. Merrill, and Patrick C. Ma.
2021. "Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?" Cancers 13, no. 5: 989.
https://doi.org/10.3390/cancers13050989
APA Style
Albandar, H. J., Fuqua, J., Albandar, J. M., Safi, S., Merrill, S. A., & Ma, P. C.
(2021). Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not? Cancers, 13(5), 989.
https://doi.org/10.3390/cancers13050989